# Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy

> **NCT02661854** · PHASE2 · UNKNOWN · sponsor: **Inmunotek S.L.** · enrollment: 186 (actual)

## Conditions studied

- Rhinitis
- Rhinoconjunctivitis

## Interventions

- **BIOLOGICAL:** MM09 Mannosylated 5.000 subcutaneous
- **BIOLOGICAL:** MM09 Mannosylated 10.000 subcutaneous
- **BIOLOGICAL:** MM09 Mannosylated 30.000 subcutaneous
- **BIOLOGICAL:** MM09 Mannosylated 50.000 subcutaneous
- **BIOLOGICAL:** MM09 Mannosylated 5.000 sublingual
- **BIOLOGICAL:** MM09 Mannosylated 10.000 sublingual
- **BIOLOGICAL:** MM09 Mannosylated 30.000 sublingual
- **BIOLOGICAL:** MM09 Mannosylated 50.000 sublingual
- **BIOLOGICAL:** Subcutaneous placebo
- **BIOLOGICAL:** Sublingual placebo

## Key facts

- **NCT ID:** NCT02661854
- **Lead sponsor:** Inmunotek S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06-21
- **Primary completion:** 2020-07
- **Final completion:** 2020-07
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2020-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02661854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02661854, "Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT02661854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*